MEDiC Life Sciences

MEDiC Life Sciences Utilizes CRISPR Functional Genomics to Discover New Therapeutic Targets and Biomarkers for Solid Tumors. The company is developing internal drug programs targeting hepatocellular carcinoma and triple-negative breast cancer, while also providing novel targets/biomarkers for other solid tumor indications pursued by its partners in oncology projects. Founded in 2020, MEDiC originated from discoveries made in Stanford University’s SPARK program.